<ddi:DDIInstance xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="ddi:instance:3_3 http://ddialliance.org/Specification/DDI-Lifecycle/3.3/XMLSchema/instance.xsd" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ddi="ddi:instance:3_3" xmlns:r="ddi:reusable:3_3" xmlns:s="ddi:studyunit:3_3" xmlns:d="ddi:datacollection:3_3" xmlns:a="ddi:archive:3_3" xmlns:c="ddi:conceptualcomponent:3_3" xmlns:cm="ddi:comparative:3_3" xmlns:g="ddi:group:3_3" xmlns:l="ddi:logicalproduct:3_3" xmlns:p="ddi:physicaldataproduct:3_3" xmlns:pi="ddi:physicalinstance:3_3" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xhtml="http://www.w3.org/1999/xhtml" xmlns:xml="http://www.w3.org/XML/1998/namespace" isMaintainable="true" scopeOfUniqueness="Agency">
  <r:URN>urn:ddi:se.researchdata:2026-179:1</r:URN>
  <r:Agency>SND</r:Agency>
  <r:ID>2026-179</r:ID>
  <r:Version>1</r:Version>
  <g:ResourcePackage>
    <r:URN>urn:ddi:se.researchdata:2026-179.ResourcePackage:2.0</r:URN>
    <r:OtherMaterialScheme>
      <r:URN>urn:ddi:se.researchdata:2026-179.OtherMaterialScheme:2.0</r:URN>
    </r:OtherMaterialScheme>
    <a:OrganizationScheme>
      <r:URN>urn:ddi:se.researchdata:2026-179.OrganizationScheme-0:2.0</r:URN>
      <a:Individual>
        <r:URN>urn:ddi:se.researchdata:2026-179.Individual-0:2.0</r:URN>
        <r:UserAttributePair>
          <r:AttributeKey>affiliation</r:AttributeKey>
          <r:AttributeValue>Department of Oncology-Pathology [K7], Karolinska Institutet</r:AttributeValue>
        </r:UserAttributePair>
        <a:IndividualIdentification>
          <a:IndividualName>
            <a:FirstGiven>Kang</a:FirstGiven>
            <a:LastFamily>Wang</a:LastFamily>
            <a:FullName>
              <r:String>Kang Wang</r:String>
            </a:FullName>
          </a:IndividualName>
          <a:ResearcherID>
            <a:TypeOfID>ORCID</a:TypeOfID>
            <a:ResearcherIdentification>0000-0001-5401-1803</a:ResearcherIdentification>
          </a:ResearcherID>
        </a:IndividualIdentification>
      </a:Individual>
      <a:Individual>
        <r:URN>urn:ddi:se.researchdata:2026-179.Individual-0:2.0</r:URN>
        <r:UserAttributePair>
          <r:AttributeKey>affiliation</r:AttributeKey>
          <r:AttributeValue>Department of Oncology-Pathology [K7], Karolinska Institutet</r:AttributeValue>
        </r:UserAttributePair>
        <a:IndividualIdentification>
          <a:IndividualName>
            <a:FirstGiven>Emmanouil</a:FirstGiven>
            <a:LastFamily>Sifakis</a:LastFamily>
            <a:FullName>
              <r:String>Emmanouil Sifakis</r:String>
            </a:FullName>
          </a:IndividualName>
          <a:ResearcherID>
            <a:TypeOfID>ORCID</a:TypeOfID>
            <a:ResearcherIdentification>0000-0001-9919-4471</a:ResearcherIdentification>
          </a:ResearcherID>
        </a:IndividualIdentification>
      </a:Individual>
      <a:Individual>
        <r:URN>urn:ddi:se.researchdata:2026-179.Individual-0:2.0</r:URN>
        <r:UserAttributePair>
          <r:AttributeKey>affiliation</r:AttributeKey>
          <r:AttributeValue>Department of Oncology-Pathology [K7], Karolinska Institutet</r:AttributeValue>
        </r:UserAttributePair>
        <a:IndividualIdentification>
          <a:IndividualName>
            <a:FirstGiven>Theodoros</a:FirstGiven>
            <a:LastFamily>Foukakis</a:LastFamily>
            <a:FullName>
              <r:String>Theodoros Foukakis</r:String>
            </a:FullName>
          </a:IndividualName>
          <a:ResearcherID>
            <a:TypeOfID>ORCID</a:TypeOfID>
            <a:ResearcherIdentification>0000-0001-8952-9987</a:ResearcherIdentification>
          </a:ResearcherID>
        </a:IndividualIdentification>
      </a:Individual>
    </a:OrganizationScheme>
  </g:ResourcePackage>
  <s:StudyUnit>
    <r:URN>urn:ddi:se.researchdata:2026-179.StudyUnit:2.0</r:URN>
    <r:UserID typeOfUserID="datasetIdentifier">2026-179</r:UserID>
    <r:Citation>
      <r:Title>
        <r:String xml:lang="sv">Longitudinell multiomisk karakterisering av patientsvar på neoadjuvant HER2-riktad behandling</r:String>
        <r:String xml:lang="en">Longitudinal Multi-Omic Characterization of Patient Responses to Neoadjuvant HER2-Targeted Therapy</r:String>
      </r:Title>
      <r:Creator>
        <r:CreatorReference>
          <r:URN>urn:ddi:se.researchdata:2026-179.Individual-0:2.0</r:URN>
          <r:TypeOfObject>Individual</r:TypeOfObject>
        </r:CreatorReference>
      </r:Creator>
      <r:Publisher>
        <r:PublisherName>
          <r:String xml:lang="sv">Karolinska Institutet</r:String>
          <r:String xml:lang="en">Karolinska Institutet</r:String>
        </r:PublisherName>
      </r:Publisher>
      <r:Publisher>
        <r:PublisherName>
          <r:String xml:lang="sv">Karolinska Institutet</r:String>
          <r:String xml:lang="en">Karolinska Institutet</r:String>
        </r:PublisherName>
      </r:Publisher>
      <r:PublicationDate>
        <r:SimpleDate>2026-06-22</r:SimpleDate>
      </r:PublicationDate>
      <r:InternationalIdentifier>
        <r:IdentifierContent>10.48723/js80-sx29</r:IdentifierContent>
        <r:ManagingAgency controlledVocabularyAgencyName="DOI">DOI</r:ManagingAgency>
      </r:InternationalIdentifier>
    </r:Citation>
    <r:Abstract>
      <r:Content xml:lang="sv">Denna datauppsättning innehåller longitudinella multiomiska profiler härledda från patienter med tidig HER2-positiv bröstcancer som deltog i den randomiserade fas II-studien PREDIX HER2 (NCT02568839). Studien jämförde neoadjuvant behandling med docetaxel, trastuzumab och pertuzumab (DHP) jämfört med trastuzumab emtansin (T-DM1). Det primära syftet med denna datainsamling var att övervaka tumörutveckling och tumörmikromiljödynamik under HER2-riktad behandling.

Datamaterial och insamling:
Datumuppsättningen omfattar multiomiska data från patientprover som samlats in vid olika tidpunkter: under behandling (efter två cykler av neoadjuvant behandling) och efter behandling (efter sex cykler av neoadjuvant behandling).

Metod och analys:
Omfattande molekylär karakterisering utfördes med hjälp av flera högkapacitetstekniker. Detta inkluderar hel-exomsekvensering (WES) för att identifiera somatiska mutationer och genomiska förändringar, RNA-sekvensering (RNA-seq) för bulktranskriptomisk profilering och proteomik för att övervaka proteinmängd. Dessutom utfördes avbildningsbaserad spatial transkriptomik med hjälp av Xenium In Situ-plattformen för att kartlägga den rumsliga organisationen av tumörmikromiljön; observera att Xeniums rumsliga data exklusivt är tillgängliga för tidpunkten för behandling.</r:Content>
      <r:Content xml:lang="en">This dataset contains longitudinal multi-omic profiles derived from patients with early HER2-positive breast cancer enrolled in the randomized phase II PREDIX HER2 clinical trial (NCT02568839). The study compared neoadjuvant treatment with docetaxel, trastuzumab, and pertuzumab (DHP) versus trastuzumab emtansine (T-DM1). The primary aim of this data collection was to monitor tumor evolution and tumor microenvironment dynamics during HER2-targeted therapy.

Data Material and Collection:
The dataset comprises multi-omic data from patient samples collected at different timepoint: on-treatment (after two cycles of neoadjuvant therapy) and post-treatment (after six cycles of neoadjuvant therapy).

Methodology and Assay:
Comprehensive molecular characterization was performed using multiple high-throughput technologies. This includes whole-exome sequencing (WES) to identify somatic mutations and genomic alterations, RNA-sequencing (RNA-seq) for bulk transcriptomic profiling, and proteomics to monitor protein abundance. Additionally, imaging-based spatial transcriptomics was performed using the Xenium In Situ platform to map the spatial organization of the tumor microenvironment; note that the Xenium spatial data is exclusively available for the on-treatment time point.

The dataset consists of the following:
1) RNA-seq/sequencing_batch/Sample.fastq.gz
Folder containing raw paired-end FASTQ files from RNA-seq. 
Each tumor sample was multiplexed across sequencing sample/lane index combinations. 
File names begin with the project-sample ID and include R1 or R2, denoting forward and reverse reads, respectively.

2) WES/sequencing_batch/Sample.fastq.gz
Folder containing raw paired-end FASTQ files from RNA-seq. 
File names begin with the project-sample ID and include R1 or R2, denoting forward and reverse reads, respectively.

3) Xenium_5k
Each subfolder contains the standardized, uncompressed output directory generated by the Xenium Ranger analysis pipeline for an individual tissue section.

The entire dataset is over 10,000 files and over 10TB in size.</r:Content>
    </r:Abstract>
    <r:Coverage>
      <r:TopicalCoverage>
        <r:URN>urn:ddi:se.researchdata:2026-179.TopicalCoverage:2.0</r:URN>
        <r:Subject xml:lang="en" controlledVocabularyID="30203" controlledVocabularyName="Standard för svensk indelning av forskningsämnen 2025">Cancer and Oncology</r:Subject>
        <r:Subject xml:lang="sv" controlledVocabularyID="30203" controlledVocabularyName="Standard för svensk indelning av forskningsämnen 2025">Cancer och onkologi</r:Subject>
        <r:Keyword xml:lang="en" controlledVocabularyID="D001943" controlledVocabularyName="MeSH">Breast Neoplasms</r:Keyword>
        <r:Keyword xml:lang="sv" controlledVocabularyID="D001943" controlledVocabularyName="MeSH">Brösttumörer</r:Keyword>
        <r:Keyword xml:lang="en" controlledVocabularyID="D018719" controlledVocabularyName="MeSH">Receptor, ErbB-2</r:Keyword>
        <r:Keyword xml:lang="sv" controlledVocabularyID="D018719" controlledVocabularyName="MeSH">ErbB-2-receptor</r:Keyword>
      </r:TopicalCoverage>
      <r:SpatialCoverage />
    </r:Coverage>
    <a:Archive>
      <r:URN>urn:ddi:se.researchdata:2026-179.Archive:2.0</r:URN>
      <a:ArchiveSpecific>
        <a:Item>
          <a:Access>
            <r:URN>urn:ddi:se.researchdata:2026-179.Archive-ArchiveSpecificType-AccessType:2.0</r:URN>
            <a:TypeOfAccess controlledVocabularyName="info:eu-repo-Access-Terms vocabulary">restrictedAccess</a:TypeOfAccess>
          </a:Access>
          <a:DataFileQuantity>2</a:DataFileQuantity>
        </a:Item>
      </a:ArchiveSpecific>
    </a:Archive>
  </s:StudyUnit>
</ddi:DDIInstance>